Re: Chicago Tribune > Today's article on CAR-T costs'/Kirk is rolling the dice
And if you have paid attention, he is going after the manufacturing and COST factors involved in GENE Therapy. They may be late to the party, but getting to the party is the important thing..
I believe getting the Hospital involved in the process is part of his game plan..
This article is primarily about blood cancers. The big prize is going to be solid tumors.. The STREET is making ZIOP a considerable underdog in this.. They may get a big surprise..
This thing is hardly over.. Kirk has Health as a 2018 major catalyst. Clarity on where they are at in this arena is probably atop that idea..I do think that a deal is being worked out between Precigen and ZIOP for controlling costs in gene therapy in oncology..Dr. Helen and Dr. Cooper look like a good one two punch for going vertical in Gene Therapy in oncology..You might look deep into Dr. Helen's background.
og